| Drug Name |
Vincristine sulfate |
| Drug ID |
BADD_D02361 |
| Description |
Vincristine is an antitumor vinca alkaloid isolated from Vinca Rosea. It is marketed under several brand names, many of which have different formulations such as Marqibo (liposomal injection) and Vincasar. Vincristine is indicated for the treatment of acute leukaemia, malignant lymphoma, Hodgkin's disease, acute erythraemia, and acute panmyelosis. vincristine sulfate is often chosen as part of polychemotherapy because of lack of significant bone–marrow suppression (at recommended doses) and of unique clinical toxicity (neuropathy). |
| Indications and Usage |
Treatment of acute lymphocytic leukemia (ALL), Hodgkin lymphoma, non-Hodgkin lymphomas, Wilms' tumor, neuroblastoma, rhabdomyosarcoma. Liposomal vincristine is indicated for the treatment of relapsed Philadelphia chromosome-negative (Ph-) acute lymphoblastic leukemia (ALL). |
| Marketing Status |
approved; investigational |
| ATC Code |
L01CA02 |
| DrugBank ID |
DB00541
|
| KEGG ID |
D02197
|
| MeSH ID |
D014750
|
| PubChem ID |
249332
|
| TTD Drug ID |
D09QVV
|
| NDC Product Code |
61703-309; 0703-4412; 48954-587; 0703-4402; 53104-7505; 54087-329; 62158-0010 |
| UNII |
T5IRO3534A
|
| Synonyms |
Vincristine | Leurocristine | Vincristine Sulfate | Sulfate, Vincristine | cellcristin | Citomid | Vincristin medac | Oncovin | Oncovine | Onkocristin | Vincasar | Farmistin | Vincasar PFS | PFS, Vincasar | Vincristin Bristol | Vintec | Vincrisul |
